RALYL Polyclonal antibody

RALYL Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 28706-1-AP

Synonyms

hnRNP core protein C like 3, HNRPCL3, hRALYL, RALY RNA binding protein like, RALYL, RNA binding Raly like protein

---

Validation Data Gallery

• 

  WB analysis using 28706-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 28706-1-AP (RALYL antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: HEK-293T cells, HeLa cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

28706-1-AP targets RALYL in WB, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: RALYL fusion protein Ag30310
• Full Name: RALY RNA binding protein-like
• Calculated Molecular Weight: 291 aa, 32 kDa
• Observed Molecular Weight: 33 kDa
• GenBank Accession Number: BC031090
• Gene Symbol: RALYL
• Gene ID (NCBI): 138046
• RRID: AB_2881197
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

RALY RNA binding protein-like (RALYL) belongs to the RALY subfamily. RALYL locates in 8q21.2, the function of which is RNA-binding and nucleotide binding. The RALYL high expression in the normal adrenal, kidney and brain (Shyamsundar et al., 2005). Furthermore, RALYL expression down-regulated correlates with mental disorder (Lee et al., 2007), Parkinson's disease (Moran et al., 2006), brain cancer (Maris et al., 2008), adrenal cancer (Giordano et al., 2009) and kidney cancer (Higgins et al., 2003). The expression of RALYL was significantly low in Clear Cell Renal Cell Carcinoma and correlated with a poor prognosis in a large number of clinical samples. Our findings showed that RALYL may be a potential therapeutic target as well as a poor prognostic